Registration as Market Architecture: The Political Economy of Pesticide Approval in Canada

1. Introduction: registration as market architecture

Every conversation about pesticide regulation in Canada eventually arrives at the same question: is this product safe? It is a reasonable question and the regulatory system is genuinely organised around answering it. Under the Pest Control Products Act, no pest control product may be manufactured, imported, sold or used in Canada unless it is registered or otherwise authorised, and registration turns on a pre-market, science-based assessment of whether risks to human health and the environment are acceptable and whether the product has acceptable value.¹

But the safety question, asked repeatedly and exclusively, crowds out a second question that matters at least as much to anyone who actually applies these products for a living: which products get registered in the first place, and why those?

This is not a question about safety. It is a question about cost. A regulatory system that requires a substantial data package, imposes a multi-year review, obliges the registrant to defend the registration again every fifteen years, and creates ongoing data-compensation liabilities is not a neutral filter that passes safe products and blocks unsafe ones. It is a toll gate with a predictable price, and that price determines which products a rational firm will bother to bring to a market of Canada's size.

This paper develops that argument. It is not an argument that the PMRA is captured, incompetent, or insufficiently protective, we find no basis for any of those claims and several reasons to reject them. It is an argument that a system optimised for one function (risk assessment) produces side effects in another domain (market structure) that nobody designed, nobody owns, and nobody is currently measuring.

1.1 Why this matters to a structural operator

For agricultural producers, the consequences of registration economics are well documented and have generated decades of minor-use policy. For structural pest management, the treatment of buildings rather than crops, the same dynamics operate with less attention and, we will argue, sharper consequences. A Winnipeg operator facing a pharaoh ant infestation in a care facility, a pyrethroid-resistant bed bug population in a rental block, or a rodent population in a grain-adjacent warehouse is working from a product list that was assembled by forces largely unrelated to those problems.

2. The statutory framework

The governing instrument is the Pest Control Products Act, SO 2002 (the PCPA), which replaced earlier legislation and took effect in its current form in the mid-2000s. Pesticides are regulated federally by the PMRA, a branch of Health Canada, under the authority of that Act.¹²

2.1 The registration requirement

The foundational provision is straightforward: before a pest control product can be approved for use and marketed in Canada it must be registered or otherwise authorised under the PCPA.¹ There is no general exemption for products registered in other jurisdictions. A product approved by the United States Environmental Protection Agency has no standing in Canada until it completes Canadian registration, and this is the single most consequential structural fact about the Canadian market.

2.2 The dual test: risk and value

Registration requires the PMRA to be satisfied on two distinct grounds. The first is that health and environmental risks are acceptable. The second, less discussed but equally binding, is that the product has acceptable value.¹ Value assessment asks whether the product actually works for its stated purpose, efficacy, in plain language.

The value test is worth pausing on because it is unusual by international standards and because it cuts both ways for practitioners. It offers genuine consumer protection: a product on a Canadian shelf has, in principle, been assessed for whether it does anything. It also raises the evidentiary burden on registrants, adding to the cost structure discussed in §3.

2.3 Transparency provisions

The PCPA was drafted as a modern transparency statute. It formalises the requirement for public consultation on major registration and re-evaluation decisions, and on policies, guidelines and codes of practice. It also permits public inspection of the information and data the PMRA reviewed in approving a product.³

This is a stronger transparency position than many comparable regimes and it substantially undercuts the more conspiratorial framings of Canadian pesticide regulation. The data room is open. The consultations are real and the comment periods are published.

3. The pre-market pathway and its cost structure

The PMRA sorts registration applications into categories by complexity, each with its own review timeline. The published structure is instructive.⁴

3.1 What the timelines actually represent

A Category A review running to 655 days is not 655 days of administrative delay. It is the period during which a multidisciplinary scientific assessment proceeds across toxicology, environmental fate, occupational exposure, dietary exposure where applicable, and value. The timeline is a reasonable reflection of the work.

But from the registrant's perspective, the timeline is a carrying cost. It is time during which capital is committed, the data package must be maintained and defended, and no revenue is generated in the Canadian market. Combined with the cost of generating the data package itself, the dominant expense, frequently running to tens of millions of dollars for a genuinely new active ingredient across all jurisdictions, the pre-market pathway establishes a threshold below which Canadian registration is simply not worth pursuing.

3.2 Throughput as evidence

The PMRA's own reporting gives a sense of the resulting flow. In 2019–2020 the agency registered 12 new active ingredients, resulting in 25 new end-use products.⁵ Of those twelve actives, seven were biopesticides, derived from bacteria, fungi, viruses, plants, animals or minerals, and five were conventional chemistry.⁵

Two observations. First, twelve new actives in a year is not a large number for an entire national market spanning agriculture, structural, industrial and consumer uses. Second, the majority being biopesticides reflects a genuine and generally welcome shift in the pipeline, but biopesticides and conventional chemistry are not interchangeable in structural applications. A biological active with a narrow target spectrum does not substitute for a residual insecticide in a wall void.

4. Post-market control: the fifteen-year cycle

Registration in Canada is not permanent. The PCPA requires the PMRA to initiate re-evaluation of each registered pesticide within fifteen years of its initial registration or of the most recent major decision affecting it.⁶⁷ The rationale is sound: science evolves, methodologies improve, and a decision made under the standards of 2010 may not survive the standards of 2025.

4.1 How re-evaluation proceeds

During re-evaluation the PMRA reviews available scientific information including data supplied by registrants, information from other federal and provincial departments, and published scientific literature.⁶ The scope of each review scales with the complexity of the science issues involved. A proposed decision is then published for a 90-day public consultation before being finalised.⁶

Outcomes range from continued registration unchanged, through amended conditions of use, label restrictions, rate reductions, additional protective equipment requirements, buffer zones, to cancellation.

4.2 The data-supply lever

The Act gives the Minister of Health authority to remove a pesticide from the market if the data required to re-evaluate it are not supplied.³ This provision is more consequential than it appears, and it is the hinge on which much of this paper's argument turns.

Consider an older active ingredient whose patent expired long ago, whose Canadian sales are modest, and which now requires a fresh data package to satisfy contemporary re-evaluation standards. The registrant faces a commercial decision: fund the studies, or allow the registration to lapse. If the Canadian revenue does not justify the expenditure, the rational choice is to let it go.

4.3 Re-evaluation throughput

In 2019–2020 the PMRA completed 16 re-evaluations and issued 10 proposed re-evaluation decisions, alongside one completed Special Review and three proposed Special Review decisions.⁵ Against a registered inventory of thousands of products, this throughput indicates that re-evaluation is a substantial, continuous programme, and one whose resourcing has been an explicit subject of internal review, with the agency examining a more sustainable approach that balances funding and workload.⁶

5. Enforcement and the compliance apparatus

The regulatory system's teeth are real and are frequently underestimated by practitioners who encounter only the registration side of it.

The Act provides substantial powers of inspection and allows fines of up to $1 million for the most serious offences.³ Registrants are obliged to report incidents relating to pesticides, and to report sales data.³

The operational scale is documented. In 2019–2020 the PMRA received 1,672 pesticide incident reports and 42 scientific studies, and conducted 1,526 inspections producing 1,695 violations, 1,606 enforcement actions and 257 compliance promotion activities.⁵

For a licensed applicator in Manitoba the practical implications are direct. Label compliance is a legal obligation enforceable by federal inspection, not a manufacturer's suggestion. Incident reporting is a statutory function of the system rather than an optional courtesy. And the sales-data obligation means the regulator has visibility into use patterns that individual operators may assume are invisible.

6. Data compensation as a barrier to entry

One of the least visible and most economically significant features of the Canadian system is the data-compensation regime under section 66 of the PCPA.

6.1 The mechanism

Test data submitted by one registrant, the data holder, can be used or relied on by other registrants, under PCPA subsections 16(5) and (5.1) for re-evaluations and 18(3) and (3.1) for special reviews.⁸ On the day a final decision statement is made public under subsection 28(5), the PMRA publishes the list of test data considered in support of the decision for which compensation may be payable.⁸ Parties then negotiate compensation.

6.2 Why this shapes the market

Data compensation is, in intent, an equity mechanism: it prevents a free-rider from building a business on another firm's multi-million-dollar toxicology package. That intent is defensible.

The structural consequence, however, is that a generic entrant's cost of entry is not merely the cost of formulation and registration administration. It includes a negotiated payment to an incumbent, on terms shaped by the incumbent's incentives. Where the negotiation is unresolved or the compensable data list is contested, entry is delayed.

The regime has itself been the subject of clarification efforts. Stakeholders indicated that the existing data protection provisions for re-evaluation and special review were neither comprehensive nor clear, prompting regulatory amendment.⁹ The PMRA has further indicated that it is developing guidelines for establishing the compensable data list, although at the time of the relevant reporting no time frame had been set.¹⁰

For our purposes the point is not that the regime is wrong. It is that the barrier to entry for a generic competitor in Canada is meaningfully higher than formulation economics alone would suggest, and that this sustains price levels and concentrates the registrant base.

7. The orphan-use problem

We can now name the distortion directly. Call a pest problem an orphan use when the population affected is large enough to matter and small enough that no registrant will fund a Canadian registration to address it.

7.1 The structure of the problem

Registration cost is approximately fixed. Expected Canadian revenue scales with market size. Registration is pursued where expected revenue exceeds cost. Therefore uses are served in descending order of market size, and there exists a cut-off below which uses are not served regardless of the severity of the underlying problem.

Crucially, the cut-off is set by market size, not by harm. A pest causing serious harm to a small population is systematically disadvantaged relative to a pest causing mild inconvenience to a large one.

7.2 Why structural uses are exposed

Agricultural minor use has a policy apparatus built around it, including programmes designed to support registrations that would not otherwise be commercially viable, and an organised grower constituency that advocates for specific registrations.

Structural pest management has weaker versions of both. The industry is fragmented among many small operators. There is no equivalent of a commodity board to aggregate demand and fund a submission. And the affected public, tenants in an infested building, patients in a care facility , is diffuse and rarely organised around a registration question.

The result is that structural uses are disproportionately represented among orphan uses, and the structural applicator's toolkit narrows in ways that reflect industry fragmentation rather than pest-management need.

8. Consequences for structural pest management in Manitoba

8.1 Palette narrowing

The cumulative effect of registration thresholds and re-evaluation attrition is a chemical palette that narrows over time unless actively replenished. Each re-evaluation cycle presents every older active with a commercial decision, and the actives most likely to be abandoned are precisely the off-patent, low-margin, narrow-use compounds, which in structural work are frequently the ones with distinctive modes of action.

8.2 Mode-of-action concentration

Palette narrowing does not proceed evenly across chemical classes. It concentrates the surviving options into fewer modes of action, because the compounds with the largest markets, and therefore the strongest case for continued registration support, cluster in the classes with broad-spectrum utility.

For resistance management this is the worst possible outcome. Rotation between modes of action is the central tool of resistance management, and rotation requires modes of action to rotate between. A palette that is narrowing by mode of action is losing resistance-management capacity faster than it is losing product count.

8.3 The consumer-channel divergence

A specific Manitoba consequence deserves note. Products available to consumers in the retail channel and products available to licensed applicators diverge in both composition and concentration. As the professional palette narrows through the mechanisms described above, the consumer palette, dominated by a small number of pyrethroid formulations with strong retail economics, does not narrow correspondingly.

The practical outcome in multi-family housing is a population of pests under sustained, uncoordinated selection pressure from consumer-channel pyrethroids, being managed by professionals whose alternative modes of action are diminishing. This is not a hypothetical interaction; it is the observable condition of urban bed bug management.

8.4 Latency and asymmetric harmonisation

Because Canadian registration is independent of United States registration, a product available to an applicator in Grand Forks may be unavailable to one in Winnipeg. The divergence is not a judgment about Canadian safety standards being higher; frequently it reflects only that the registrant did not pursue Canadian registration.

The practitioner-facing consequence is that technical literature, trade press, manufacturer training and online professional discussion are overwhelmingly American, and describe a toolkit that does not map onto Canadian legal availability. A Manitoba operator must therefore maintain an independent picture of what is actually registered here, and the effort of doing so is itself a cost imposed by the regulatory architecture.

9. The unpriced resistance externality

Resistance is a classic depletable common-pool resource. Susceptibility to a given mode of action is finite, shared among all users, and degraded by use. Each individual application is rational; their aggregate exhausts the resource.

9.1 Where the current system does and does not engage

The PCPA's risk-and-value framework engages resistance only indirectly. Value assessment asks whether a product works, which in principle could capture declining field performance. Re-evaluation could in principle incorporate resistance considerations. Neither is a resistance-management instrument in the way that, say, a rotation requirement embedded in label conditions would be.

Meanwhile the consumer channel, where the largest volume of uncoordinated pyrethroid application occurs in urban structural settings, operates with no resistance-management architecture whatsoever. A homeowner buying an aerosol is not informed that the product's mode of action is the same one their neighbour used last week, nor that the population being selected is shared between their units.

9.2 The mismatch of timescales

Resistance develops on a timescale of years. Registration of a new mode of action takes, at minimum, the 285–655 days of a Category A review⁴ preceded by years of discovery and data generation. Re-evaluation operates on a fifteen-year cycle.⁶⁷

These timescales are not aligned. A resistance problem that becomes field-apparent in year three cannot be answered by a regulatory process whose fastest response is measured in years and whose review cycle is measured in decades. The gap is filled, in practice, by applicators improvising with a narrowing palette.

10. Political economy: who shapes the palette

It follows from the cost structure that the firms capable of sustaining Canadian registrations are those able to amortise fixed regulatory costs across large global portfolios, the major agrochemical manufacturers. This is a description of an incentive structure, not an allegation of misconduct.

10.1 The consultative apparatus

Canada maintains formal stakeholder consultation, including the Pest Management Advisory Council, which convenes stakeholders on matters including the statutory review of the PCPA.¹¹ Advisory structures of this kind are genuine transparency instruments. They are also, inevitably, more accessible to organisations with dedicated regulatory affairs capacity than to fragmented small-business sectors, which describes structural pest control in Canada precisely.

10.2 What is not represented

The interests systematically under-represented in registration decisions are those of the diffuse affected public: tenants in multi-family housing whose infestation risk is shaped by the available palette, care-facility residents, and small operators. None of these groups has a natural mechanism for advocating that a particular mode of action be maintained on the Canadian market.

The practical consequence is a market where product availability tracks global commercial strategy more closely than it tracks Canadian pest-management need, with no actor in the system whose job it is to notice.

11. Reform debate and the statutory review

The PCPA contains provision for parliamentary review, and the process could be initiated after June 2020.¹¹ The PMRA conducted internal analysis of the legislation and consulted external stakeholders on potential issues, with broader public consultation planned subsequently.¹¹

Notably, Pest Management Advisory Council members indicated that the PCPA remains fit for purpose.¹¹ This is a significant data point and worth taking seriously rather than dismissing. The statute's architecture, risk and value, mandatory re-evaluation, transparency, enforcement powers, is defensible and, by international comparison, strong.

Our argument is consistent with that assessment. The distortions described here do not arise from defects in the Act. They arise from the interaction between a well-designed regulatory framework and a market whose size does not support the fixed costs that framework imposes. That is an economics problem wearing regulatory clothing, and amending the safety provisions of the statute would not address it.

11.1 What would address it

Without advocating specific policy, the analysis points to instruments that operate on cost rather than on standards: mechanisms analogous to agricultural minor-use support extended to structural uses; joint review arrangements that reduce duplicative data generation across jurisdictions; and explicit resistance-management criteria within value assessment, such that maintaining mode-of-action diversity is treated as a public good with regulatory standing.

Each carries trade-offs beyond the scope of this paper. We note only that they act on the mechanism this analysis actually identifies, whereas the debates that dominate public discussion , whether the PMRA is too lax or too strict, act on a mechanism that is largely not the binding constraint.

12. Limitations and open questions

Cost figures are not public at the granularity required. The argument depends on registration costs being large relative to Canadian structural-market revenue. We regard this as well established in general terms, but we have not located audited, Canada-specific cost data by submission category, and we have not asserted specific figures.

Attrition is asserted structurally rather than measured. We argue that re-evaluation produces commercially-driven registration withdrawal. Testing this requires a longitudinal dataset of Canadian structural registrations classified by withdrawal reason. We are not aware of a published dataset of this kind. Until one exists, §4.2 should be read as a mechanism whose existence is clear and whose magnitude is unquantified.

Reporting-period specificity. The throughput and enforcement figures cited are from the PMRA's 2019–2020 annual reporting.⁵ They illustrate scale; they should not be read as current-year values.

Mode-of-action concentration is not quantified here. The claim in §8.2 is mechanistically sound but we have not constructed the time series of registered structural actives by IRAC mode-of-action classification that would demonstrate it empirically. That analysis is feasible from public registration data and we intend to attempt it.

13. Conclusion

The Canadian pesticide regulatory system is, on the evidence, a competent and transparent risk-assessment apparatus. It applies a dual test of risk and value,¹ mandates re-evaluation on a fifteen-year cycle,⁶⁷ publishes proposed decisions for 90-day consultation,⁶ opens its data to public inspection,³ and backs the regime with inspection powers and penalties reaching $1 million.³ Stakeholders on its own advisory council consider the statute fit for purpose.¹¹ We find no persuasive case that the system is failing at what it was designed to do.

It is, however, doing something else at the same time. By imposing a largely fixed cost on entry and a recurring cost on continued registration, it establishes a commercial threshold that determines which pest problems are addressable with registered chemistry in Canada. That threshold is indifferent to harm. It selects for market size.

For structural pest management in Manitoba the consequences are concrete: a narrowing palette, concentrating modes of action, a consumer channel applying uncoordinated selection pressure to the same populations professionals are trying to manage, and a resistance externality that no part of the current architecture prices.

The debate we are having, is the PMRA too permissive, or not permissive enough, is a debate about the height of the gate. The more consequential question is about the toll, who can afford it, and which problems consequently go unaddressed. That question is not currently anybody's responsibility, which is precisely why it deserves to be asked.

References

1. Health Canada, Pest Management Regulatory Agency. Pest control products (pesticides) acts and regulations. Government of Canada. Outlines the requirement that products be registered or otherwise authorised under the PCPA prior to marketing, and the pre-market risk and value assessment. https://www.canada.ca/en/health-canada/services/consumer-product-safety/pesticides-pest-management/public/protecting-your-health-environment/pest-control-products-acts-and-regulations-en.html
2. Canada Gazette, Part I. Regulations Amending the Pest Control Products Regulations (2022). Describes the PMRA's mandate and the PCPA's governance of pesticides through pre- and post-market scientific risk assessment and risk management. https://gazette.gc.ca/rp-pr/p1/2022/2022-06-11/html/reg4-eng.html
3. Health Canada. Statutory Review of the Pest Control Products Act. Sets out the Act's 15-year re-evaluation requirement, the Minister's authority to remove a product where re-evaluation data are not supplied, incident and sales reporting obligations, inspection powers, penalties to $1 million, and public inspection of data reviewed for registration. https://www.canada.ca/en/health-canada/services/consumer-product-safety/pesticides-pest-management/public/consultations/statutory-review-pest-control-products-act.html
4. Canada Pesticide Registration: application categories and review timelines. Category A 285–655 days; Category B 158–425 days; lower categories scaled to complexity. https://www.proregulations.com/canada-pesticide-registration.html
5. Health Canada, Pest Management Regulatory Agency. Annual Report 2019–2020. Source for registration throughput (12 new active ingredients, 25 end-use products, 7 biopesticides), re-evaluation and special review completions, 1,672 incident reports, and 1,526 inspections with 1,695 violations and 1,606 enforcement actions. https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/pesticides-pest-management/corporate-plans-reports/annual-report-2019-2020.html
6. Health Canada, Pest Management Regulatory Agency. Re-evaluation Program. Describes the statutory 15-year re-evaluation requirement, sources of information considered, the 90-day public consultation on proposed decisions, and the agency's review of programme sustainability. https://www.canada.ca/en/health-canada/services/consumer-product-safety/pesticides-pest-management/public/protecting-your-health-environment/pesticide-registration-process/reevaluation-program.html
7. Analysis of PCPA re-evaluation and special review provisions, including the general 15-year re-evaluation cycle and its statutory basis. https://www.lexology.com/library/detail.aspx?g=779d0145-cc90-4c4b-b134-c15d735ab6fa
8. Health Canada, PMRA. Guidance for registrants and data holders for use or reliance on test data considered in support of re-evaluation and special review decisions. Sets out the section 66 data compensation process and PCPA subsections 16(5), 16(5.1), 18(3), 18(3.1) and 28(5). https://www.canada.ca/en/health-canada/services/consumer-product-safety/reports-publications/pesticides-pest-management/policies-guidelines/guidance-registrants-data-holders-use-reliance-test-data-considered-support-reevaluation-special-review-decisions.html
9. Canada Gazette, Part I. Regulatory amendment rationale noting stakeholder views that data protection provisions for re-evaluation and special review were neither comprehensive nor clear. https://gazette.gc.ca/rp-pr/p1/2022/2022-06-11/html/reg4-eng.html
10. Commentary on PMRA clarification of data compensation in re-evaluation and special review contexts, including the compensable data list and the absence of a published time frame for associated guidelines. https://www.lexology.com/library/detail.aspx?g=779d0145-cc90-4c4b-b134-c15d735ab6fa
11. Health Canada. Pest Management Advisory Council, 2020 Meeting Summary Report. Records the parliamentary review process available after 29 June 2020, PMRA internal analysis and stakeholder consultation, and PMAC members' view that the PCPA remains fit for purpose. https://www.canada.ca/en/health-canada/services/consumer-product-safety/pesticides-pest-management/public/advisory-bodies/pest-management-advisory-council/2020-meeting-summary-report.html